Walgreens Boots Alliance Reports Mixed Q3 2025 Results Amid Pharmacy Growth
Walgreens Boots Alliance delivered a fiscal third-quarter performance marked by revenue growth but earnings disappointment. Sales climbed 7.2% year-over-year to $39.0 billion, exceeding analyst expectations, while adjusted EPS fell to $0.38 from $0.63 in the prior-year period.
The U.S. Retail Pharmacy segment drove top-line results with 7.8% sales growth to $30.7 billion, fueled by a 14.6% surge in comparable pharmacy sales. Management attributed the earnings shortfall to tax rate impacts, lower retail sales, and reduced equity earnings from pharmaceutical distributor Cencora.
Log in to Reply
Log in to comment your thoughtsComments
Related Articles
|Square
Get the BTCC app to start your crypto journey
Get started today Scan to join our 100M+ users